<DOC>
	<DOCNO>NCT00007956</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient recurrent refractory lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Recurrent Refractory Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity monoclonal antibody mono-dgA-RFB4 patient recurrent refractory B-cell lymphoma express CD22 antigen . - Determine pharmacokinetic profile drug patient . - Correlate pharmacokinetic parameter biologic effect and/or toxicity drug patient . - Determine whether clinical response patient occur low , equal , high dose historical response induce similar drug . OUTLINE : This dose-escalation study . Patients stratify accord number circulate tumor cell peripheral blood ( 50/mm3 vs 50/mm3 less ) . Patients receive monoclonal antibody Mono-dgA-RFB4 IV 4 hour day 1 , 3 , 5 . Patients achieve complete , partial , minimal remission receive additional course therapy every 4 week absence unacceptable toxicity . Cohorts 3-6 patient receive escalate dos monoclonal antibody mono-dgA-RFB4 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose-limiting toxicity . Patients achieve complete remission stable partial remission follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 20-25 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory Bcell lymphoma least 1 standard chemotherapy regimen Low , intermediate , high grade CD22 antigen least 30 % tumor cell flow cytometry No lymphoblastic lymphoma , Bcell chronic lymphocytic leukemia , Bcell preBcell acute lymphocytic leukemia , hairy cell leukemia Measurable disease Positive bone marrow consider measurable Circulating tumor cell peripheral blood consider measurable No CNS disease ( leptomeningeal parenchymal ) No lymphomatous infectious pulmonary parenchymal disease No baseline/pleural effusion Ineligible refuse autologous allogeneic bone marrow transplantation NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count great 50,000/mm^3 Absolute granulocyte count great 750/mm^3 Hepatic : Bilirubin le 1.5 mg/dL SGPT le 2 time upper limit normal Albumin great 75 % low limit normal Renal : Creatinine great 1.4 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : Ejection fraction great 40 % MUGA echocardiogram Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No human antimouse antibody ( HAMA ) level great 1 microgram/mL No condition may require stenting ureter , stabilization impend pathological fracture , relief airway , bowel , biliary tract obstruction No concurrent illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 2 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroids unless receive stable maintenance dose prior therapy Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>